AU2008275304B2 - Recurrent gene fusions in prostate cancer - Google Patents

Recurrent gene fusions in prostate cancer Download PDF

Info

Publication number
AU2008275304B2
AU2008275304B2 AU2008275304A AU2008275304A AU2008275304B2 AU 2008275304 B2 AU2008275304 B2 AU 2008275304B2 AU 2008275304 A AU2008275304 A AU 2008275304A AU 2008275304 A AU2008275304 A AU 2008275304A AU 2008275304 B2 AU2008275304 B2 AU 2008275304B2
Authority
AU
Australia
Prior art keywords
gene
erg
tmprss2
family member
etv1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008275304A
Other languages
English (en)
Other versions
AU2008275304A1 (en
Inventor
Arul M. Chinnaiyan
Scott Tomlins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/825,552 external-priority patent/US10041123B2/en
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU2008275304A1 publication Critical patent/AU2008275304A1/en
Priority to AU2009316693A priority Critical patent/AU2009316693B2/en
Application granted granted Critical
Publication of AU2008275304B2 publication Critical patent/AU2008275304B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2008275304A 2007-07-06 2008-07-03 Recurrent gene fusions in prostate cancer Ceased AU2008275304B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009316693A AU2009316693B2 (en) 2007-07-06 2009-11-18 Recurrent gene fusions in prostate cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/825,552 2007-07-06
US11/825,552 US10041123B2 (en) 2005-09-12 2007-07-06 Recurrent gene fusions in prostate cancer
PCT/US2008/069204 WO2009009432A2 (en) 2007-07-06 2008-07-03 Recurrent gene fusions in prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009316693A Division AU2009316693B2 (en) 2007-07-06 2009-11-18 Recurrent gene fusions in prostate cancer

Publications (2)

Publication Number Publication Date
AU2008275304A1 AU2008275304A1 (en) 2009-01-15
AU2008275304B2 true AU2008275304B2 (en) 2012-07-26

Family

ID=40210565

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008275304A Ceased AU2008275304B2 (en) 2007-07-06 2008-07-03 Recurrent gene fusions in prostate cancer

Country Status (6)

Country Link
EP (3) EP2604701B1 (enExample)
JP (4) JP5529732B2 (enExample)
AU (1) AU2008275304B2 (enExample)
CA (2) CA2814246A1 (enExample)
WO (1) WO2009009432A2 (enExample)
ZA (1) ZA201000128B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718369B2 (en) 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2008039774A1 (en) 2006-09-25 2008-04-03 Mayo Foundation For Medical Education And Research Extracellular and membrane-associated prostate cancer markers
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
JP5433572B2 (ja) 2007-07-06 2014-03-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｉｐｏｌ１−ｅｔｖ１遺伝子再編成
JP5529732B2 (ja) * 2007-07-06 2014-06-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
JP5800817B2 (ja) * 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
JP6044935B2 (ja) 2013-03-11 2016-12-14 学校法人日本大学 新規ｐｉポリアミド
KR102241063B1 (ko) 2013-03-15 2021-04-16 얀센 파마슈티카 엔.브이. 예측성 바이오마커에 대한 검정법
EP2975078A1 (en) 2014-08-14 2016-01-20 Omya International AG Surface-treated fillers for breathable films
WO2017061128A1 (ja) 2015-10-08 2017-04-13 凸版印刷株式会社 ピロールイミダゾール含有ポリアミドを用いた標的二本鎖核酸分子の濃縮方法およびキット
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
CN114634913A (zh) * 2022-02-27 2022-06-17 复旦大学 肿瘤硬脑膜转移模型的构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033187A2 (en) * 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0232967B1 (en) 1986-01-10 1993-04-28 Amoco Corporation Competitive homogeneous assay
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
ATE282716T1 (de) 1989-07-11 2004-12-15 Gen Probe Inc Verfahren zur amplifikation von nukleinsäuresequenzen
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
DE69333366T2 (de) 1992-10-30 2004-09-16 The General Hospital Corp., Boston Ein neues zellzyklus kontrollprotein
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
KR100334858B1 (ko) 1993-02-19 2006-01-27 니뽄 신야쿠 가부시키가이샤 핵산공중합체를함유하는의약조성물
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US6019978A (en) 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
EP0914335A2 (en) 1996-03-15 1999-05-12 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
DE69738687D1 (de) 1996-04-12 2008-06-26 Phri Properties Inc Sonden, kits und assays
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
EP1005546A2 (en) 1997-02-25 2000-06-07 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO1998039636A1 (en) 1997-03-07 1998-09-11 Clare Chemical Research Llc Fluorometric detection using visible light
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
ES2324503T3 (es) 1997-04-10 2009-08-07 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, genes pca3 y metodos de uso.
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
AU756549B2 (en) 1997-07-11 2003-01-16 Crucell Holland B.V. Interleukin-3 gene therapy for cancer
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
WO2000001850A2 (en) 1998-07-02 2000-01-13 Gen-Probe Incorporated Molecular torches
JP2003528029A (ja) 1998-08-14 2003-09-24 アヴェンティス ファーマシューティカルズ インコーポレイテッド 遺伝子治療用のアデノウイルス配合物
WO2000012738A1 (en) 1998-08-27 2000-03-09 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6828429B1 (en) 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
US6541205B1 (en) 1999-05-24 2003-04-01 Tosoh Corporation Method for assaying nucleic acid
US7060436B2 (en) 2000-06-17 2006-06-13 Third Wave Technologies, Inc. Nucleic acid accessible hybridization sites
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003023057A2 (de) 2001-09-06 2003-03-20 Adnagen Ag Verfahren und diagnose-kit zur selektionierung und/oder zum qualitativen und/oder quantitativen nachweis von zellen
EP1474433A4 (en) 2002-02-20 2005-02-23 Sirna Therapeutics Inc VALIDATION AND IDENTIFICATION OF RNA INTERFERENCE FACILITATED TARGETS USING SHORT INTERFERENT NUCLEIC ACID (siNA)
CA2524572C (en) 2003-05-01 2018-07-10 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch having enhanced sensitivity to the presence of a mismatch
WO2005038054A1 (en) 2003-10-20 2005-04-28 Zicai Liang METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES
GB0327726D0 (en) 2003-11-28 2003-12-31 Isis Innovation Method
US7696337B2 (en) 2004-08-27 2010-04-13 Gen-Probe Incorporated Composition kits and methods for performing amplification reactions
JP5529732B2 (ja) * 2007-07-06 2014-06-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033187A2 (en) * 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer

Also Published As

Publication number Publication date
EP2604701B1 (en) 2015-11-04
JP6035634B2 (ja) 2016-11-30
JP2010532663A (ja) 2010-10-14
CA2692441A1 (en) 2009-01-15
EP2604701A3 (en) 2013-10-02
CA2692441C (en) 2020-01-21
JP6404378B2 (ja) 2018-10-10
EP3018216B1 (en) 2018-09-12
JP2016019542A (ja) 2016-02-04
EP3018216A1 (en) 2016-05-11
CA2814246A1 (en) 2009-01-15
AU2008275304A1 (en) 2009-01-15
EP2167689B1 (en) 2012-10-31
WO2009009432A2 (en) 2009-01-15
WO2009009432A3 (en) 2009-06-04
JP5529732B2 (ja) 2014-06-25
EP2604701A2 (en) 2013-06-19
EP2167689A2 (en) 2010-03-31
JP2017108751A (ja) 2017-06-22
ZA201000128B (en) 2011-03-30
JP2014094015A (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
AU2008275304B2 (en) Recurrent gene fusions in prostate cancer
AU2009316693B2 (en) Recurrent gene fusions in prostate cancer
US10041123B2 (en) Recurrent gene fusions in prostate cancer
HK1187055A (en) Recurrent gene fusions in prostate cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired